Haorui Shen1, Yali Ji1, Daobin Zhou1, Yan Zhang1, Wei Wang1, Jian Sun2, Wei Zhang1. 1. a Department of Hematology , Peking Union Medical College Hospital , Beijing , People's Republic of China. 2. b Department of Pathology , Peking Union Medical College Hospital , Beijing , People's Republic of China.
Abstract
PURPOSE: To investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL). METHODS: In total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3-8 courses of chemotherapy. The expression of PD-L1 in tumor tissues from nine PTCL patients was also detected. RESULTS: sPD-L1 was higher in PTCL patients at diagnosis compared to healthy subjects (P < 0.0001). Patients in the intermediate/high-risk disease group had a higher level of sPD-L1 than patients in the low-risk group (P = 0.0003). Elevated sPD-L1 (≥176.30 pg/ml) was the only biomarker for PTCL that retain statistical significance in multivariate analysis. Patients in the low-risk group with sPD-L1 ≥ 176.30 pg/ml had an adverse prognosis. Histological analysis showed that the expression of PD-L1 in tissues was positively correlated with sPD-L1 levels in plasma (Spearman = 0.9177, P = 0.0013). CONCLUSIONS: sPD-L1 is a sensitive biomarker predicting clinical outcomes in PTCL.
PURPOSE: To investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL). METHODS: In total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3-8 courses of chemotherapy. The expression of PD-L1 in tumor tissues from nine PTCL patients was also detected. RESULTS: sPD-L1 was higher in PTCL patients at diagnosis compared to healthy subjects (P < 0.0001). Patients in the intermediate/high-risk disease group had a higher level of sPD-L1 than patients in the low-risk group (P = 0.0003). Elevated sPD-L1 (≥176.30 pg/ml) was the only biomarker for PTCL that retain statistical significance in multivariate analysis. Patients in the low-risk group with sPD-L1 ≥ 176.30 pg/ml had an adverse prognosis. Histological analysis showed that the expression of PD-L1 in tissues was positively correlated with sPD-L1 levels in plasma (Spearman = 0.9177, P = 0.0013). CONCLUSIONS: sPD-L1 is a sensitive biomarker predicting clinical outcomes in PTCL.
Entities:
Keywords:
Peripheral T-cell lymphoma; prognosis; programmed cell death ligand 1
Authors: Eugene Shenderov; Karim Boudadi; Wei Fu; Hao Wang; Rana Sullivan; Alice Jordan; Donna Dowling; Rana Harb; Joseph Schonhoft; Adam Jendrisak; Michael A Carducci; Mario A Eisenberger; James R Eshleman; Jun Luo; Charles G Drake; Drew M Pardoll; Emmanuel S Antonarakis Journal: Prostate Date: 2021-02-26 Impact factor: 4.104
Authors: Mahlatse C M Kgokolo; Katherine Anderson; Shalate C Siwele; Helen C Steel; Luyanda L I Kwofie; Mike M Sathekge; Pieter W A Meyer; Bernardo L Rapoport; Ronald Anderson Journal: Front Oncol Date: 2022-02-11 Impact factor: 6.244